Recently, it has been demonstrated that Etoposide, a topoisomerase II inhibitor, can induce apoptosis in MDM2 -overexpressing tumor cells by inhibition of MDM2 synthesis. We have previously shown that E2F -1 overexpression induces apoptosis of MDM2 -overexpressing sarcoma cells, which is related to the inhibition of MDM2 expression. Therefore, the present study was designed to investigate the in vitro and in vivo effect of combined treatment of adenovirus -mediated E2F -1 and topoisomerase II inhibitors on the growth inhibition and apoptosis in human sarcoma cells. Two human sarcoma cell lines, OsACL and U2OS, were treated with topoisomerase II inhibitors ( Etoposide and Adriamycin ) , alone or in combination with adenoviral vectors expressinggalactosidase ( Ad -LacZ ) or E2F -1 ( Ad -E2F -1 ) . E2F -1 expression was confirmed by Western blot analysis. Ad -E2F -1 gene transfer at a low dose ( multiplicity of infection, 2 ) markedly increased the sensitivity of human sarcoma cells to topoisomerase II inhibitor treatment. This cooperative effect of E2F -1 and topoisomerase II inhibitors was less marked in SAOS -2 cells ( p53 and pRb null ) . Topoisomerase II inhibitors also cooperated with E2F -1 overexpression to enhance tumor cell killing in an in vivo model using xenografts in nude mice. When combined with Adriamycin or Etoposide, E2F -1 adenovirus therapy resulted in approximately 95% and 85% decrease in tumor size, respectively, compared to controls ( P < .05 ) . These results suggest a new chemosensitization strategy that is effective in MDM2 -overexpressing tumors and may have clinical utility. Cancer Gene Therapy ( 2001 ) 8, 241 ± 251
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steosarcomas are rare malignant tumors that arise from the skeletal system. There has been improvement in patient survival rates with a shift in treatment strategies from radical amputation to that of limb salvage surgery coupled with high -dose chemotherapy. Even with progressively more aggressive therapy, however, the 5-year survival rate plateaus at approximately 50± 60%.
1,2 Current multidrug combinations have high associated toxicity and are often not well tolerated, resulting in an overall reduction of dose intensities and an increased incidence of drug resistance. 2 ± 4 There is a need for novel therapies in those patients incurable by multimodality treatments. Better understanding of cellular processes and the role of oncogenes and tumor suppressor genes may lead to the development of alternative treatment strategies.
The inactivation of p53 by mutation or deletion plays a role in the development of both bone and soft -tissue sarcomas. 5, 6 Indeed, the p53 gene has been deleted and rearranged in a high percentage of osteosarcomas, and the development of sarcomas is a requisite part of the tumor spectrum in the Li -Fraumeni family syndrome that involves germ -line p53 mutations. 5 ± 10 Amplification of MDM2, the protein product of the mdm2 oncogene, has also been implicated in sarcoma tumorigenesis and has been correlated with a more aggressive tumor phenotype in both soft -tissue sarcomas and osteosarcomas.
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MDM2 binds to and inactivates p53, inhibiting the ability of p53 to induce cell cycle arrest and apoptosis. 12 ± 15 Indeed, MDM2 overexpression seems to represent an alternative mechanism of p53 inactivation. 16, 17 There is an evidence to suggest that the oncogenic effect of MDM2 is independent of p53, for it appears that MDM2 overexpression can also transform cells in culture in the absence of a functioning p53 gene. 18, 19 MDM2 also binds to the retinoblastoma gene product, pRB, thereby impairing the ability of pRB to inhibit E2F transcriptional activity and to induce of G1 arrest. 20 MDM2 has also been shown to bind directly to the E2F -1 transcription factor and stimulate cell cycle progression. 21 The E2F family of transcription factors modulates cell growth and the cell cycle progression. 22 The best characterized member of this family, E2F -1, activates transcription of genes involved in the G1 -to S -phase transition. 23 Early studies suggested that E2F -1 functioned as an oncogene based on its ability to stimulate cell proliferation when overexpressed, to transform rat embryonic fibroblasts in cooperation with Ras, and to promote tumorigenesis in mice. 24 ± 27 Somewhat paradoxically, more recent studies showed that E2F -1 also has properties of a tumor suppressor, based on its ability to induce apoptosis. Homozygous E2F -1 null ( knockout ) mice demonstrate increased cell proliferation and tumor formation in several tissues. Overexpression of E2F -1 has been shown to induce apoptosis in many tumor cells.
28 ± 34 E2F -1 may also play a role in mediating apoptosis following exposure to DNA -damaging treatments, such as chemotherapeutic agents or ionizing radiation. 35 ± 37 Our previous studies have shown that adenovirus -mediated E2F -1 gene transfer efficiently induces apoptosis in human MDM-2 overexpressing sarcoma cell lines, which is related to the inhibition of MDM -2 expression. 38 Over the last few decades, a variety of different chemotherapeutic agents have been studied in sarcomas. 2 ± 4,39,40 Unfortunately, the majority have demonstrated only marginal activity with low response rates of 15% or less.
3,4 Some of the more active drugs are the topoisomerase II inhibitors, including Adriamycin (doxorubicin ) and Etoposide. 41 ± 44 The mechanism remains incompletely understood, but it has been demonstrated that Etoposide can induce apoptosis in human sarcoma cell lines, which overexpress MDM -2 by inhibition of MDM-2 synthesis. 36 Induction of E2F -1 in these tumor cells correlates with their chemosensitivity to topoisomerase inhibitors, whereas loss of E2F -1 expression contributes to the resistance to these chemotherapeutic agents, implicating that E2F -1 may mediate the cytotoxicity of some drugs in tumor cells. 36, 37 In the present studies, the in vitro and in vivo additive effects of adenovirus -mediated E2F -1 and topoisomerase II inhibitors were evaluated. Our observations clearly show that adenovirus -mediated E2F -1 gene transfer can markedly sensitize human osteosarcoma cells to topoisomerase II inhibitors, leading to an additive effect on apoptotic cell death. These data support a new chemosensitization strategy for human sarcoma gene therapy.
MATERIALS AND METHODS

Cell lines and culture conditions
Human osteosarcoma cell lines, OsACL and U2OS ( both overexpress MDM-2 oncoprotein ) , were purchased from ATCC (Rockville, MD ). OsACL cells were cultured in RPMI-1640 medium and U2OS cells were cultured in McCoy's 5A medium. The medium was supplemented with 10% heat -inactivated fetal bovine serum (FBS ) and penicillin / streptomycin ( 100 units /mL ) . All cell culture reagents were obtained from Gibco /BRL ( Bethesda, MD ) and all chemotherapeutic agents from Sigma ( St. Louis, MO ) . Cells were cultured in a 5% CO 2 incubator at 378C, and the medium was changed depending on the cell growth condition.
Adenoviral vectors
Three replication -defective recombinant adenoviral vectors were used. Ad5CMV-E2F -1 vector has been deleted in the E1 subunit and contains the transgene E2F -1 under the control of the CMV promoter. 38 Ad5CMV-LacZ ( generously provided by Dr. Brent French ) was used as a control vector that expresses nuclear-localized -galactosidase under control of the same promoter. 45 The recombinant adenoviruses containing wild type p53 (Ad -p53 ) were generously gifted by Dr. Bert Vogelstein. 46 All vectors were propagated in the 293 cell line and titers were determined using standard plaque assays. 47 
Adenovirus infections and combined treatments
For infection, 1Â10 6 cells were plated in 10 -cm tissue culture plates. The following day, the medium was removed, and the adenoviral vectors were added in 1 mL -MEM at multiplicity of infection (MOI ) of 2 for Ad -E2F -1 and AdLacZ. Mock infection was performed by treatment of cells with vehicle (media) only. One hour after incubation at 378C, the medium was removed, and 10 mL fresh RPMI or McCoy's 5A with 5% FBS was added. For the combined treatments, cells were infected with viruses as described above, and then 1 hour later, the medium was replaced with 10 mL fresh RPMI or McCoy's 5A with 5% FBS containing chemotherapeutic agents. Cells were then cultured at 378C and harvested at a 3-day time point for analysis.
Western blot analysis
Cells were harvested at 3 days after treatments and cell lysates were prepared as described previously. 38, 48 Equal amounts of cellular protein (50 g ) were electrophoresed in sodium dodecyl sulfate polyacrylamide gels and transferred to a Hybond -PVDP membrane ( Amersham, Arlington Heights, IL ). The membrane was first incubated with the following primary antibodies: the mouse anti -E2F -1 monoclonal antibody ( Santa Cruz Biotechnology, Santa Cruz, CA ) and mouse± antihuman -CPP32 mAb (Transduction Lab, Lexington, KY ) ; and then with antimouse Ig, peroxidase -linked, species -specific whole antibody ( Amersham ). Enhanced chemiluminescence reagents were used to detect the signals according to the manufacturer's instructions (Amersham ).
Cellular viability assays
Cells were plated in 10-cm plates and treated as above. The cells' appearance and morphology were observed by standard light microscopy. Cell viability was determined at day 3 by trypan blue exclusion. Cells were stained with trypan blue (0.2% final concentration ) for 5 minutes and counted using a hematocytometer.
Cell cycle analysis and apoptosis assay
Both adherent and nonadherent cells were harvested, washed once with phosphate -buffered saline ( PBS ), and fixed in 70% (vol /vol ) ethanol at À 208C for up to 1 week. Cells were pelleted, washed once with PBS, and resuspended in propidium iodide solution (50 g /mL propidium iodide, 0.5 mg /mL RNase in PBS, pH 7.4 ) for 30 minutes in the dark. FACS analysis was performed at 3 days following treatments. Flow cytometric analysis was performed on a FACScan Flow Cytometer ( Becton Dickinson, San Jose, CA ). The data from 10,000 cells were collected and analyzed using CellFIT Cell -Cycle Analysis Software ( Version 2.01.2 ). DNA content of the subdiploid peak, which indicated apoptotic cells, was determined by FACS analysis.
The in situ TUNEL assay further confirmed internucleosomal DNA strand breaks characteristic of apoptosis. Cells were fixed in 4% formaldehyde in PBS ( pH 7.4 ) for 15 minutes at room temperature. After centrifugation, cells were resuspended in 80% ethanol and stored at 48C for up to 1 week. A TdT-FragELTM DNA fragmentation detection kit ( Calbiochem, Oncogene Research Products, Cambridge, MA ) was used to detect apoptosis according to instructions provided by the manufacturer.
In vivo combined treatment of transplanted human sarcoma cells
To evaluate the ability of AdCMV-E2F -1 plus systemic Etoposide or Adriamycin to suppress tumor growth in vivo, tumors were formed by injecting 1Â10 7 OsACL cells into athymic Balb /c nu /nu male mice ( 6± 8 weeks, Charles River Laboratories, Wilmington, MA ). Anesthesia was induced by intraperitoneal (i.p. ) injection of Ketamine ( 37.5 mg /kg) and Xylene (5 mg /kg ). The cells were injected subcutaneously into the bilateral flanks of the mice. Twelve days later, palpable tumors (about 250 mm 3 ) were randomized to be directly injected with AdCMV-E2F -1 (1Â10 9 pfu ), AdCMV-LacZ (1Â10 9 pfu ) , or control To determine the possible mechanism of this inhibition, cell cycle analysis was performed. As shown in Figure 1B , Etoposide and Adriamycin caused a G2 arrest in 34.0% and 62.6% of OsACL cells, respectively. Similarly, they arrested the cell cycle at G2 phase in 51.6% and 71.6% of U2OS cells, respectively. These data suggest that topoisomerase II agents can inhibit the cell growth by arresting the cell cycle at G2 phase, but did not effectively induce cell death.
The addition of adenovirus -mediated E2F -1 to topoisomerase inhibitors, Etoposide or Adriamycin, acts additively to produce a significant loss of cell viability A recent report showed that endogenous E2F -1 induction correlates with tumor cell sensitivity to some DNA -damaging agents including the topoisomerase II inhibitors. 36, 37 In the present study, we examined whether exogenous E2F -1 overexpression could increase the sensitivity of human sarcoma cells (in which there is no detectable basal expression of E2F -1 ) to Etoposide and Adriamycin. First, to determine an optimal MOI of adenovirus at which E2F -1 protein was significantly overexpressed, Western blot analysis was performed. As shown in Figure 2A , an MOI of 2 leads to an overexpression of E2F -1. No obvious cytotoxicity was noted at this MOI. Neither Etoposide nor Adriamycin alone led to the accumulation of endogenous or basal E2F -1 expression in either cell line. When Etoposide and Adriamycin were combined with adenovirus -E2F -1, however, the expression of exogenous adenovirus -mediated E2F -1 protein was significantly increased. Therefore, the combined treatments enhance the expression of exogenous E2F -1, as shown in Figure 2A .
Cellular proliferation and cell viability were then assessed to evaluate the effects on cell growth. As shown in Figure  2B , the combined treatment of adenovirus -E2F -1 and Adriamycin or Etoposide resulted in a much greater loss of cell viability at a concentration near IC 50 , compared to Adriamycin or Etoposide alone in OsACL cells. Similar results were obtained in U2OS cells, as shown in Figure 2C . These data show that the addition of Ad -E2F -1 to the topoisomerase II inhibitors leads to a significant loss of viability in human osteosarcoma cells compared to treatment with either E2F -1 or chemotherapeutic agents alone.
The combination treatment of adenovirus -mediated E2F -1 and topoisomerase II inhibitors induces apoptosis independent of p53, but may be related to caspase cascade activation Previous studies from our laboratory indicated that adenovirus -mediated E2F -1 at an MOI of 100 induced apoptosis in human osteosarcoma cell lines. 38 In the present study, we 
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have shown that an MOI of 2 leads to overexpression of exogenous E2F -1. There was no obvious sub -G1 peak ( representing apoptotic cells) in DNA histograms in either cell line treated by Ad -E2F -1 at an MOI of 2, as shown in Figure 3A and B. However, there was a significant sub -G1 peak in both cell lines after the combination treatments of adenoviral -mediated E2F -1 and Adriamycin or Etoposide, as shown in Figure 3 . Apoptosis is characterized by internucleosomal degradation of genomic DNA. Using the in situ TUNEL ssay, it is possible to confirm that DNA cleavage has occurred and free 3 H -OH groups are generated by cellular endonucleases. At 72 hours after infection, the combination of Ad -E2F -1 and topoisomerase inhibitors ( Adrimycin or Etoposide ) ± infected cells demonstrated abundant TUNEL staining. In contrast, neither the mock -infected nor the drugs, or the viruses alone showed significant evidence of internucleosomal DNA fragmentation (Fig 4 ) . These results indicate that Ad -E2F -1 combined with topoisomerase II inhibitors act additively to induce apoptosis. Cell morphology demonstrated typical changes characteristic of apoptotic cell death, including cell shrinkage, cytoplasmic blebbing, chromatin condensation, nuclear fragmentation, and formation of apoptotic bodies (data not shown) . These changes were more obvious in the combination treatments than in either E2F -1 or drug treatment alone, and were not seen at all in mock -infected or Ad5CMV-LacZ ± infected cells.
It had been thought previously that p53 was essential for E2F -1± mediated apoptosis. 30, 33 Recent studies, however, showed that p53 is not always required. 18, 19 p53 is normally undetectable in both OsACL and U2OS cells. 31 As the present data show, Western blots demonstrated that p53 remained undetectable after the combined treatments (data not shown) . To further determine whether p53 is involved in the combined treatment ±induced apoptosis, we treated another human osteosarcoma cell line, SAOS -2 (p53 and pRb null ), with Ad -E2F -1 plus Ad -p53, alone or combined with Etoposide or Adriamycin. The data, as shown in Figure 5 , revealed a cooperative effect of Ad -E2F -1 plus topoisomerase II inhibitor therapy in SAOS -2 cells, albeit of a lesser magnitude than that seen in U2OS and OsACL cells. Exogenous expression of p53 in combination with E2F -1/ topoisomerase II inhibitor therapy resulted in somewhat enhanced cytotoxicity. These data suggest that wild type p53 function may maximize the cytotoxicity of the E2F -1 plus topoisomerase II combination therapy.
Our recent studies suggest a role for the caspase cascade in E2F -1± mediated apoptosis. 48 To evaluate the role of caspase cascade activation in apoptosis induced by the combined treatment of Ad -E2F -1 and topoisomerase II inhibitors, Western blot analysis of PARP, a substrate of the proenzyme CPP32, was performed. In OsACL cells, an apoptosis -specific PARP cleavage fragment ( 85± 90 kDa ) was present in the combined treatment, but not obvious in the controls, or Ad -E2F -1 or drugs alone (Fig 6) . Taken together, these data suggest that the caspase cascade may be a common mechanism.
Up -regulation of E2F -1 expression induced by the combination treatment of E2F -1 adenovirus and Etoposide or Adriamycin may be related to the down -regulation of MDM2 expression MDM2 has been shown to suppress E2F -1 ±mediated apoptosis. 48, 49 To determine the role of MDM2 in combined treatment± induced apoptosis, we performed the Western blots to analyze MDM2 expression. The data were shown in Figure 6 . Although the down -regulation of MDM2 protein induced by the combined E2F -1 +topoisomerase II inhibitors is relatively subtle in U2OS cells, it is significant compared to the controls including the mock, Ad -LacZ, Ad -E2F -1, Adriamycin, and Ad -LacZ plus Adriamycin in OsACL cells when densitometry is performed (Student's t test, P <.005 ). Also, at this time point, there is up-regulation of E2F -1 expression in cells treated with Ad -E2F -1 plus topoisomerase II inhibitors, but no changes in the controls, the adenovirus -treated, or the topoisomerase II ± treated cells ( see Figure 2A ). It appears that the up -regulation of E2F -1 caused by the combination treatment of E2F -1 adenovirus and Etoposide or Adriamycin may be related to the MDM2 protein degradation.
In vivo treatment of transplanted human sarcoma cells ( combination therapy in vivo )
Subcutaneous tumors in bilateral flanks of mice were randomized and treated as described with local injection of 0.9% saline (control ), LacZ adenovirus (vehicles ) , or E2F -1 adenovirus, followed by an i.p. injection of Adriamycin, Etoposide, or 0.9% saline. Athymic nude mice ( Balb /c ) were given a total of five chemotherapy treatments over a period of 1 month. The total virus dose for each injection was 1Â10 9 pfu, and was administered as indicated in the Materials and Methods. Use of E2F -1 adenovirus alone reduced mouse tumor size by approximately 60% by day 30. The drugs ( Adriamycin or Etoposide ) alone or combined with LacZ reduced tumor burden by approximately 40% and 45%, respectively, as shown in Figure 7A and B, which was not statistically significant (P > .05 ). However, when combined with Adriamycin or Etoposide, E2F -1 adenovirus caused approximately 95% and 85% decrease in tumor size, respectively, compared to controls and this was statistically significant (P < .05 ) (Fig 7, A and B ). Tumors were excised on day 30 ( Fig 7D ) . Final tumor burden in mice treated only with control, vehicles, Ad -E2F -1, Adriamycin, or Etoposide was 2.8 0.3, 2.9 0.5, 1.2 0.3, 1.8 0.3, and 2.1 0.3 g, respectively. When both E2F -1 viruses and a topoisomerase II inhibitor ( either Adriamycin or Etoposide ) were combined, the tumors weighed 0.30 0.1 and Figure 5 . The loss of viability after the combined treatment of Ad -E2F -1 and Etoposide or Adriamycin in SAOS -2 cells. SAOS -2 cells ( lacking both p53 and pRb ) were treated with mock infection, AdLacZ, Ad -E2F -1, Ad -p53, Etoposide, Adriamycin, or their combinations. The MOI for Ad -E2F -1 is 2, and for Ad -p53, an MOI of 10 was used. Cells were harvested at 3 days following the treatments for cell viability using the trypan blue method. Results are expressed as the percentage of viable cells and represent the mean of three independent experiments SEM. YANG, DONG, ELLIOTT, ET AL: ADENOVIRUS-MEDIATED E2F-1 GENE TRANSFER AND TOPOISOMERASE II INHIBITORS 0.7 0.1 g, respectively, and were statistically significant compared to the controls ( P <.005 ) ( Fig 7C ) .
DISCUSSION
Overexpression of E2F -1 has been shown to induce apoptosis in several cell types, both normal and malignant. 33 ± 36,50 ± 55 The mechanisms by which E2F -1 induces apoptosis are not fully understood, but it has been suggested that apoptosis results from incompatible signals for proliferation and cell cycle arrest. 33, 49, 50, 56 Our previous studies have shown that adenovirus -mediated E2F -1 gene transfer resulted in rapid and efficient apoptosis of MDM2 -overexpressing osteosarcoma and fibrosarcoma cells. 38 We found that E2F -1 overexpression Figure 7 . In vivo antitumor effect of the combination treatment of Ad -E2F -1 ( Ad5CMV -E2F -1 ) and Etoposide or Adriamycin. Following subcutaneous administration of 1Â10 7 OsACAL cells, palpable tumors were randomized to receive a local injection of controls ( saline ) , vehicles, Ad5CMV -LacZ, and Ad5CMV -E2F -1 followed by i.p. injection of Adriamycin or Etoposide. Athymic nude mice ( Balb / c ) were given six treatments over a period of 1 month. The total virus dose was 6Â2Â1Â10
9 pfu viral particles. The mice were monitored, the tumors were measured, the volumes were calculated ( A and B ) . On day 30, the tumors were excised ( D ) and weighed ( C ) . The results are expressed as the mean from each treatment group + standard deviation (A, B, C). The differences in size or weight in OsACL tumors treated by the combined treatment of Ad5CMV -E2F -1 and Adriamycin compared to the controls were highly statistically significant by the end of the experiments ( day 30, P < .005 ) .
Cancer Gene Therapy, Vol 8, No 4, 2001 inhibited MDM2 expression and was associated with activation of the caspase pathway. The decrease in MDM2 levels was not accompanied by any detectable rise in p53 levels.
Many chemotherapeutic agents kill cancer cells by activating apoptosis. Type II topoisomerases, ATP -dependent enzymes that catalyze topological changes in DNA, are key targets for a number of these chemotherapy drugs. DNA topoisomerase II is essential for cellular processes such as chromosome segregation, DNA replication, transcription, recombination, and chromatin organization. It is thought that topoisomerase II inhibitors stabilize the cleavable complex stage of the catalytic cycle, allowing an increased portion of complexes to be cleaved. The stabilized complexes are then converted into double -stranded DNA breaks, which are toxic to the cell. Two isoforms have been identified, and their protein levels appear to increase in G2 / M phase. 2 ± 4,57,58 One of the principal obstacles in the clinical efficacy of topoisomerase II inhibitors in sarcoma patients has been the rapid emergence of cellular resistance. 58 Many chemotherapeutic agents have pleiotropic cellular effects, and the precise mechanism of Etoposide and Adriamycin resistance is unknown. 58, 59 Recent studies showed that ICRF -193, another topoisomerase II inhibitor, acts by trapping topoisomerase II in a closed clamp configuration, making it inaccessible to the actions of Etoposide. Interestingly, the combination of ICRF -193 and DNA damage significantly decreased the viability of E2F -1 ±overexpressing cells via E2F -1± mediated apoptosis. 36 Our current results show the marked sensitization of osteosarcoma cells to Etoposide and Adriamycin by adenovirus -mediated E2F -1 gene transfer both in vitro and in vivo. This combination treatment induced apoptotic cell death to a significantly greater extent than either treatment alone. Our observations are consistent with those of Meng et al, 60 who found that an increase of E2F -1 expression enhanced the cytotoxic effects of Etoposide and Adriamycin in human medulloblastoma, glioma, lung, colon, and bladder cancer cell lines. The enhanced sensitivity of human sarcoma cells to topoisomerase II inhibitors by the Ad -E2F -1 gene transfer may be the result of molecular events during late S -phase and G2 -phase. It has been demonstrated that mutations in E2F -1 that block cyclin A binding trigger an S -phase cell cycle checkpoint that leads to cell cycle G2 -arrest, apoptosis, and sensitivity to DNAdamaging agents. 61, 62 In an analogous manner, topoisomerase II inhibition coupled with DNA damage and unregulated E2F -1 may also trigger this S -phase checkpoint, arrest the cell cycle at G2 -phase, and then induce apoptosis. In human sarcoma cells, cyclin A kinase phosphorylates DP -1, the heterodimeric partner of E2F -1, in late S -phase and suppresses the DNA -binding activity of E2F -1, which allows the cells to complete S-phase. Other studies have shown that E2F -1 is induced by Adriamycin and Etoposide administration. 36, 37 MDM2 degradation may also explain our current results. We have previously demonstrated that adenovirus -mediated E2F -1 overexpression at an MOI of 100 resulted in a decreased level of MDM2, 38 although in the present studies, no obvious change of MDM2 levels occurred after the Ad -E2F -1 infection alone at an MOI of 2. When this infection was combined with the topoisomerase II inhibitors (especially Adriamycin ) in OsACL cells, however, there was a significant decrease in MDM2 levels, compared to the control groups, indicating that this combined treatment± mediated growth inhibition and apoptosis may result, at least in part, from the inhibition of MDM2 function. Alternatively, MDM2 down -regulation may simply correlate with the induction of apoptosis, but play no functional role in promoting apoptotic cell death. Although the mechanisms underlying this decrease in MDM2 levels are unclear, MDM2 is known to be a caspase 3 /CPP32 substrate. 62 Therefore, the decrease in MDM2 levels may be related to caspase cleavage. 63, 64 Although p53 classically has been thought to be involved in E2F -1 ±induced apoptosis, 30, 33 it is now clear that p53 is not always required. 18, 19, 38, 49, 53 It has been demonstrated that E2F -1 induced p53 -independent apoptosis in SAOS-2 cells (p53 and Rb null ) and p53 null mice. 65 A more recent study showed that E2F -1 cooperates with topoisomerase II inhibitors to selectively augment apoptosis which is p53-independent. 36, 37 Furthermore, adenovirus -mediated E2F -1 gene transfer has recently been shown to induce apoptosis in human melanoma, glioma, breast cancer, ovarian cancer, esophageal cancer, and head and neck cancer cells in a p53 -independent manner. 38,48,52 ± 54,56,66 In the present studies, p53 protein levels remained undetectable by Western blot analysis after the combination treatments, suggesting that p53 overexpression is not necessary for this process. Furthermore, combined treatment of SAOS -2 cells with Ad -E2F -1 and topoisomerase II inhibitors resulted in a cooperative effect on cell death, albeit less marked than that seen in U2OS and OsACL cells. It is possible that, despite our inability to detect an increase in p53 expression, wild type p53 does play a role in maximizing the cytotoxicity of the E2F -1/topoisomerase II inhibitor combination therapy.
We also evaluated the in vivo antitumor effects of combination therapy with Ad -E2F -1 and topoisomerase II inhibitors ( Etoposide and Adriamycin ). It has been well documented that adenovirus -mediated E2F -1 has an antitumor efficacy in a variety of tumors attributable to both the E2F -1 tumor suppressor gene and the adenovirus delivery vector. From this point of view, the adenovirus -mediated E2F -1 could be regarded as a drug. Our in vivo experiments were designed to mimic the clinical situation in which efficacy of the adenovirus drug (with or without chemotherapy ) will be compared to clinical outcome with traditional chemotherapy. In the animal model of human osteosarcoma, E2F -1 adenovirus alone or a single topoisomerase II inhibitor alone had a relatively minimal antitumor effect. There was, however, a significantly enhanced response when these modalities were combined. These data offer the possibility of enhanced antitumor activity with lowerthan -normal doses of both topoisomerase II inhibitors and E2F -1 adenoviruses. This has the potential to decrease dose -dependent chemotherapy side effects, increase patient quality of life, and perhaps increase the efficacy of cancer chemotherapy. 
CONCLUSION
Transduction of genes that sensitize tumor cells to chemotherapeutic agents represents a promising strategy for cancer gene therapy. In the present studies, we demonstrated that transduction of the E2F -1 gene significantly enhances the sensitivity of human sarcoma cells to topoisomerase II inhibitors, and this combination treatment results in significant synergistic activity both in vitro and in vivo. This represents a novel chemosensitization and potentially useful strategy for human cancer gene therapy. Future studies will focus on the potential clinical utility of this approach and evaluate the differential effects on tumor cells and normal tissues. 
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